A phase II study for the evaluation of quinine as a modulator of multidrug resistance in non-Hodgkin's lymphoma

European Journal of Cancer

Volumn 43, Issue 1, 2007, Pages 53-54

  Soubeyran, Pierre ^a   Masmoudi, Amine ^a   Blanc Bisson, Christelle ^a   Quénel, Nathalie ^a   Hœrni, Bernard ^a   Bellott, Ricardo ^a   Robert, Jacques ^a   Soubeyran, Isabelle ^a   Donamaria, Catherine ^a   Molimard, Matthieu ^b  

^a INSTITUT BERGONIÉ   (France)

^b UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

Epirubicin; Multidrug resistance reversal; Non Hodgkin's lymphoma; P glycoprotein; Quinine

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; EPIRUBICIN; ETOPOSIDE; IFOSFAMIDE; PREDNISOLONE; QUININE; VINCRISTINE;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER PATIENT; CARDIOTOXICITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; DISEASE FREE SURVIVAL; DRUG MONITORING; HEARING LOSS; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MULTIDRUG RESISTANCE; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THERAPY DELAY; TINNITUS; TREATMENT OUTCOME; TREATMENT RESPONSE; VERTIGO;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; LYMPHOMA, NON-HODGKIN; MIDDLE AGED; QUININE;

EID: 33846024351     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2005.11.044     Document Type: Article

References (8)

1. Miller T.P., Grogan T.M., Dalton W.S., et al. P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. J Clin Oncol 9 (1991) 17-24
2. Wilson W.H., Bates S.E., Fojo A., et al. Controlled trial of dexverapamil, a modulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapy. J Clin Oncol 13 (1995) 1995-2004
3. Solary E., Caillot D., Chauffert B., et al. Feasibility of using quinine, a potential multidrug resistance-reversing agent, in combination with mitoxantrone and cytarabine for the treatment of acute leukemia. J Clin Oncol 10 (1992) 1730-1736
4. Solary E., Witz B., Caillot D., et al. Combination of quinine as a potential reversing agent with mitoxantrone and cytarabine for the treatment of acute leukemias: a randomized multicenter study. Blood 88 (1996) 1198-1205
5. Solary E., Drenou B., Campos L., et al. Quinine as a multidrug resistance inhibitor: a phase 3 multicentric randomized study in adult de novo acute myelogenous leukemia. Blood 102 (2003) 1202-1210
6. Bennis S., Faure P., Chapey C., et al. Cellular pharmacology of lipophilic anthracyclines in human tumor cells in culture selected for resistance to doxorubicin. Anticancer Drugs 8 (1997) 610-617
7. Al-Ismail S.A., Whittaker J.A., and Gough J. Combination chemotherapy including epirubicin for the management of non-Hodgkin's lymphoma. Eur J Cancer Clin Oncol 23 (1987) 1379-1384
8. Wade J.R., Kelman A.W., Kerr D.J., et al. Variability in the pharmacokinetics of epirubicin: a population analysis. Cancer Chemother Pharmacol 29 (1992) 391-395